BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Institute for Bioengineering of Catalonia - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Institute for Bioengineering of Catalonia
X-ORIGINAL-URL:https://ibecbarcelona.eu
X-WR-CALDESC:Events for Institute for Bioengineering of Catalonia
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Madrid
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Madrid:20240705T100000
DTEND;TZID=Europe/Madrid:20240705T120000
DTSTAMP:20260418T075441
CREATED:20240618T140841Z
LAST-MODIFIED:20240618T140841Z
UID:118701-1720173600-1720180800@ibecbarcelona.eu
SUMMARY:IBEC Seminar: Shahid Uddin
DESCRIPTION:Developability assessment of biologics and formulation of novel molecules\nShahid Uddin\, PhD\, MBA\, Senior Director of Drug Product\, Formulation & Stability within the CMC department at Immunocore\, UK \nIt’s vital to ensure appropriate assessment of molecules at the early research phase is carried out to risk mitigate movement into the development phase. This ensures the best risk of success with minimal usage of resources and finances. This presentation will highlight the procedures for assessing developability and also showcases the challenges associated with administering low-concentration biologics.
URL:https://ibecbarcelona.eu/event/ibec-seminar-shahid-uddin/
LOCATION:IBEC\, floor 11\, Tower I\, Baldiri Reixac 4-8\, 08028 Barcelona\, Spain
CATEGORIES:IBEC Seminar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Madrid:20240717T150000
DTEND;TZID=Europe/Madrid:20240717T150000
DTSTAMP:20260418T075441
CREATED:20240620T104046Z
LAST-MODIFIED:20240712T061459Z
UID:118724-1721228400-1721228400@ibecbarcelona.eu
SUMMARY:IBEC Seminar: Sabina Quader
DESCRIPTION:Nanomedicine to Tackle Unmet Medical Needs in CNS Disorders\nSabina Quader\, Innovation Center of NanoMedicine (iCONM)\, Kawasaki Institute of Industrial Promotion\, Kawasaki\, Kanagawa 210-0821 Japan \nThe brain is undoubtedly the body’s most essential and intricate organ\, and brain disorders are closely tied to this intricacy. Categorized as “CNS diseases\,” a wide range of brain-related conditions – including Alzheimer’s\, dementia\, Amyotrophic Lateral Sclerosis\, stroke\, brain tumors\, and more – present daunting challenges. Regrettably\, many of these diseases currently lack adequate treatment\, underscoring the urgent need for innovative and multidimensional efforts to combat these persistent problems. In this regard\, nanomedicine shows tremendous potential for diagnosing and treating many life-threatening diseases\, including cardiovascular and genetic disorders\, CNS diseases\, and cancers1. The field of nanomedicine is constantly revolutionizing healthcare with innovative approaches to tackling severe health issues. However\, it is also crucial to actively translate these novel approaches more effectively. In our laboratory at the Innovation Center of NanoMedicine (iCONM)\, we aim to effectively bridge innovation and translation. Our nanomedicine platform is based on polymeric micelles that are constructed from poly(ethylene glycol)-b-poly(amino acids) (PEG-PAA) copolymers and have already demonstrated significant promise through their clinical translation potential2. The PEG-PAA copolymers are highly biocompatible and have the unique ability to engineer versatile\, dynamic covalent chemistry-based approaches to link the cargo with the carriers; this feature ultimately improves spatiotemporal control over drug release kinetics\, which is one of the critical properties of drug-loaded nanocarriers\, along with size and surface properties. In this presentation\, optimal design features of nanomedicine will be discussed\, focusing on treating CNS diseases\, mainly brain cancers3\,4. An overview of our Japan-Spain international collaborative research focused on drug delivery to hypothalamic neurons for tackling obesity will also be presented5. \nReferences– \n\nQuader and K. Kataoka*\, Mol Ther\, 25 (2017) 1501.\nCabral\, K. Miyata\, K. Osada\, K. Kataoka*\, Chem. Rev.\, 118 (2018) 6844.\nKinoh\, S. Quader\, H. Shibasaki\, X. Liu\, A. Maity\, T. Yamasoba\, H. Cabral*\, K. Kataoka*\,ACS Nano\, 14 (2020) 10127.\nQuader*\, X. Liu\, K. Toh\, Y.-L. Su\, A. R. Maity\, A. Tao\, W. K. D. Paraiso\, Y. Mochida\, H. Kinoh\, H. Cabral\, K. Kataoka*\, Biomaterials\, 267 (2021)120463.\nJ Garcia-Chica\, WK D Paraiso\, S Zagmutt\, A Fosch\, A Reguera\, X Ariza\, S Alzina\, L Sanchez-Garcia\, S Fukushima\, K Toh\, N Casals\, D Serra\, L Herrero\, J Garcia\, K Kataoka\, X Ariza\, S Quader*\, R Rodriguez-Rodriguez*\, Nanomedicine targeting brain lipid metabolism as a feasible approach for controlling the energy balance\,  Sci. 11 (2023) 2336-2346\n\n\nDr. Quader did her Ph.D. in Synthetic Organic Chemistry from Griffith University\, Brisbane\, Australia 2007. Following her Ph.D.\, she started working as a Research Chemist at Research Directions Pty Ltd\, Brisbane\, Australia. In 2010\, she joined Professor Kazunori Kataoka’s world-renowned biomaterial research laboratory at the Materials Engineering Department of Tokyo University with a Japanese government -funded prestigious JSPS postdoctoral fellowship. After completing two years of JSPS fellowship\, she continued her work at the same laboratory for another two years as Project Researcher. Since 2015\, she has been an integral part of the Innovation Center of NanoMedicine (iCONM)\, Kawasaki\, Japan\, as a Senior Research Scientist and\, as of 2023\, as a Deputy Principal Research Scientist. Dr. Quader’s area of expertise lies in developing stimuli-sensitive nanomaterials tailored for targeted drug delivery to address challenging diseases. Dr. Quader is currently a principal investigator in multiple projects and overseeing international research activities at iCONM as Chief Coordinator of Global Partnership. One of her international collaborative research endeavors\, “COnCorD\,” was one of the three bilateral projects awarded by the Spanish State Agency for Research (AEI) and the Japanese Medical Research Agency (AMED) as a result of an invitation for joint project proposals from early-stage researchers in Japan and Spain in the “Nanomedicine” research area.
URL:https://ibecbarcelona.eu/event/ibec-seminar-sabina-quader/
LOCATION:Sala Dolors Aleu\, Cluster II\, IBEC\, Baldiri i Reixac\, Barcelona
CATEGORIES:IBEC Seminar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Madrid:20240719T100000
DTEND;TZID=Europe/Madrid:20240719T110000
DTSTAMP:20260418T075442
CREATED:20240604T101628Z
LAST-MODIFIED:20240604T101628Z
UID:118268-1721383200-1721386800@ibecbarcelona.eu
SUMMARY:IBEC Seminar: Carlos Moreno Yruela
DESCRIPTION:Semi-synthetic nucleosomes to stabilize and image enzyme-chromatin interactions\nCarlos Moreno Yruela\, Researcher in Chemical Biology\, EPFL\, Switzerland \nChromatin structure regulates gene expression and is tightly controlled by histone post-translational modifications. SIRT7 is a histone lysine deacylase found to maintain oncogenic gene expression profiles supporting tumor growth and \nmetastasis. Interestingly\, the activity of SIRT7 is fully dependent on binding to nucleosomes within chromatin. This feature has limited the development of inhibitors and chemical probes to further dissect its role in cancer progression. Here\, we develop nucleosome-based tools for structural characterization and high-throughput screening. Thanks to 2- and 3-fragment native chemical ligation methods\, we introduced synthetic peptides into the structure of histone H3\, to install either mechanism-based thiourea crosslinkers or fluorescence quenchers at the positions of known SIRT7 substrates. First\, mechanism-based crosslinking nucleosomes allowed us to stabilize the interaction of SIRT7 with its nucleosome substrates and obtain structures by cryoEM. The different complexes revealed a multivalent and non-canonical nucleosome binding mechanism\, and specific residues responsible for targeting different substrates within the nucleosome. Second\, nucleosomes with acyllysine fluorescence quenchers and a neighboring fluorophore proved to be SIRT7-activated fluorogenic substrates and will be used for high-throughput screening and single-molecule biophysical characterization. All in all\, we developed a strategy to stabilize enzyme-chromatin interactions for detailed structural studies\, as well as a platform for the development of translatable SIRT7-targeting cancer therapeutics. \n\nCarlos studied Chemistry at the University of Zaragoza and obtained his M.Sc. in Drug Discovery from the University of Surrey (UK). He obtained his Ph.D. in Chemical Biology from the University of Copenhagen in 2019\, on the development of assays and chemical probes for histone deacetylases in the laboratory of Prof. Christian Adam Olsen. He stayed 3 more years in Copenhagen as postdoctoral fellow\, working on the newly found lactyl-lysine modification of histones. In 2022\, Carlos moved to EPFL Lausanne (Switzerland) thanks to a postdoctoral grant from the Independent Danish Research Council\, where he uses protein semi-synthesis to generate complex in vitro systems for translatable biophysical studies and anticancer drug development. Carlos is now an independent postdoctoral fellow of the Swiss National Science Foundation.
URL:https://ibecbarcelona.eu/event/ibec-seminar-carlos-moreno-yruela/
LOCATION:Sala Dolors Aleu\, Cluster II\, IBEC\, Baldiri i Reixac\, Barcelona
CATEGORIES:IBEC Seminar
END:VEVENT
END:VCALENDAR